Marlyn J Mayo (Marlyn Mayo)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 15

Top Topics

Ulcerative Colitis

Top Venues

Hepatology (Baltimore, Md.)

Alimentary pharmacology & therapeutics

Clinical liver disease

This page only lists publications with an associated author ORCID identifier.

Publications

David E J Jones, Ulrich H W Beuers, Alan Bonder, Marco Carbone, Emma L Culver, Jessica Katharine Dyson, Robert G Gish, Bettina E Hansen, Gideon M Hirschfield, Rebecca Jones, Kris Kowdley, Andreas E Kremer, Keith D Lindor, Marlyn J Mayo, George Mells, James Neuberger, Martin Prince, Mark G Swain, Atsushi Tanaka, Douglas Thorburn, Michael Trauner, Palak J Trivedi, Martin Weltman, Andrew D Yeoman, Cynthia Levy
Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here? Hepatology (Baltimore, Md.) (2024)
Marlyn J Mayo, John M Vierling, Christopher L Bowlus
Editorial: The evolving paradigms and treatments for primary biliary cholangitis-Authors' reply. Alimentary pharmacology & therapeutics 59 (2) (2023)
Andreas E Kremer, Marlyn J Mayo, Gideon M Hirschfield, Cynthia Levy, Christopher L Bowlus, David E Jones, Jeff D Johnson, Charles A McWherter, Yun-Jung Choi
Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis. Hepatology (Baltimore, Md.) 80 (1) (2023)
Andreas E Kremer, Marlyn J Mayo, Gideon M Hirschfield, Cynthia Levy, Christopher L Bowlus, David E Jones, Jeff D Johnson, Charles A McWherter, Yun-Jung Choi
Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis. Hepatology (Baltimore, Md.) 80 (1) (2023)
Andreas E Kremer, Marlyn J Mayo, Gideon M Hirschfield, Cynthia Levy, Christopher L Bowlus, David E Jones, Jeff D Johnson, Charles A McWherter, Yun-Jung Choi
Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis. Hepatology (Baltimore, Md.) 80 (1) (2023)
Andreas E Kremer, Marlyn J Mayo, Gideon M Hirschfield, Cynthia Levy, Christopher L Bowlus, David E Jones, Jeff D Johnson, Charles A McWherter, Yun-Jung Choi
Seladelpar treatment reduces interleukin-31 and pruritus in patients with primary biliary cholangitis. Hepatology (Baltimore, Md.) (2023)
Marlyn J Mayo, John M Vierling, Christopher L Bowlus
Editorial: The evolving paradigms and treatments for primary biliary cholangitis-Authors' reply. Alimentary pharmacology & therapeutics 59 (2) (2023)
Andreas E Kremer, Marlyn J Mayo, Gideon M Hirschfield, Cynthia Levy, Christopher L Bowlus, David E Jones, Jeff D Johnson, Charles A McWherter, Yun-Jung Choi
Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis. Hepatology (Baltimore, Md.) (2023)
Andreas E Kremer, Marlyn J Mayo, Gideon M Hirschfield, Cynthia Levy, Christopher L Bowlus, David E Jones, Jeff D Johnson, Charles A McWherter, Yun-Jung Choi
Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis. Hepatology (Baltimore, Md.) 80 (1) (2023)
Gideon M Hirschfield, Mitchell L Shiffman, Gideon M Hirschfield, Kris V Kowdley, John M Vierling, Cynthia Levy, Andreas E Kremer, Ehud Zigmond, Pietro Andreone, Stuart C Gordon, Christopher L Bowlus, Eric J Lawitz, Richard J Aspinall, Daniel S Pratt, Karina Raikhelson, Maria S Gonzalez-Huezo, Michael A Heneghan, Sook-Hyang Jeong, Alma L Ladrón de Guevara, Marlyn J Mayo, Georgios N Dalekos, Joost Paulus Hubertus Drenth, Ewa Janczewska, Barbara A Leggett, Frederik Nevens, Víctor Vargas, Eli Zuckerman, Christophe Corpechot, Eduardo Fassio, Holger Hinrichsen, Invernizzi Pietro, Palak J Trivedi, Lisa Forman, David E J Jones, Stephen D Ryder, Mark G Swain, Alexandra Steinberg, Pol F Boudes, Yun-Jung Choi, Charles A McWherter, null null
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study. Hepatology (Baltimore, Md.) (2023)
Marlyn J Mayo, John M Vierling, Christopher L Bowlus, Cynthia Levy, Gideon M Hirschfield, Guy W Neff, Michael R Galambos, Stuart C Gordon, Brian B Borg, Stephen A Harrison, Paul J Thuluvath, Aparna Goel, Mitchell L Shiffman, Mark G Swain, David E J Jones, Palak J Trivedi, Andreas E Kremer, Richard J Aspinall, David A Sheridan, Yvonne Dörffel, Ke Yang, Yun-Jung Choi, Charles A McWherter
Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis. Alimentary pharmacology & therapeutics (2023)
Marlyn J Mayo
Mechanisms and molecules: What are the treatment targets for primary biliary cholangitis? Hepatology (Baltimore, Md.) 76 (2) (2022)
Adriaan J van der Meer, Maren H Harms, Christophe Corpechot, Douglas Thorburn, Invernizzi Pietro, Harry L A Janssen, Pier M Battezzati, Frederik Nevens, Keith D Lindor, Annarosa Floreani, Cyriel Y Ponsioen, Marlyn J Mayo, Albert Parés, Andrew L Mason, Kris V Kowdley, Palak J Trivedi, Gideon M Hirschfield, Karen Schmidt, George N Dalekos, Nikolaos K Gatselis, Xavier P D M J Verhelst, Willem J Lammers, Bettina E Hansen, Henk R van Buuren, Adriaan J van der Meer, null null
Liver transplant-free survival according to alkaline phosphatase and GLOBE score in patients with primary biliary cholangitis treated with ursodeoxycholic acid. Alimentary pharmacology & therapeutics 56 (9) (2022)
Mark R Pedersen, Marlyn J Mayo
Managing the Symptoms and Complications of Cholestasis. Clinical liver disease 15 (3) (2020)
Fiorella Murillo Perez, Gideon M Hirschfield, Christophe Corpechot, Annarosa Floreani, Marlyn J Mayo, Adriaan van der Meer, Cyriel Y Ponsioen, Willem J Lammers, Albert Parés, Invernizzi Pietro, Marco Carbone, Pier Maria Battezzati, Frederik Nevens, Kris V Kowdley, Douglas Thorburn, Andrew L Mason, Palak J Trivedi, Keith D Lindor, Tony Bruns, George N Dalekos, Nikolaos K Gatselis, Xavier Verhelst, Harry L A Janssen, Bettina E Hansen, Aliya Gulamhusein, null null
Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response. Alimentary pharmacology & therapeutics 50 (10) (2019)